Christopher Simon - 15 May 2026 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: President & CEO, Director
Issuer ticker: HAE
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 17:28:15 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon

Key filing fact

Christopher Simon filed Form 4 for HAEMONETICS CORP (HAE) on 19 May 2026.

Key facts

This page summarizes Christopher Simon's Form 4 filing for HAEMONETICS CORP (HAE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 17:28.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674993 Primary reporting owner

Simon, Christopher

Relationship: President & CEO, Director
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Tax liability

Transaction value
Shares: -9,681
Change %: -2.6%
Price: $56.29^*
Shares after: 366,360
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F2

HAE transaction

Common Stock

Award

Transaction value
Shares: +78,344
Change %: +21%
Price
Shares after: 444,704
Date: 15 May 2026
Ownership: Direct
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

Footnote F2

This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.

Footnote F3

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Footnote F4

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.